Phencyclidine and glutamate agonist LY379268 stimulate dopamine D2High receptors: D2 basis for schizophrenia

@article{Seeman2008PhencyclidineAG,
  title={Phencyclidine and glutamate agonist LY379268 stimulate dopamine D2High receptors: D2 basis for schizophrenia},
  author={P. Seeman and H. Guan},
  journal={Synapse},
  year={2008},
  volume={62}
}
It has previously been reported that the glutamate ionotropic antagonist phencyclidine directly inhibits the release of prolactin in anterior pituitary cells in culture, suggesting that phencyclidine has a dopamine (DA)‐like action on prolactin‐releasing cells. It has also been reported that the glutamate metabotropic agonist LY379268 can stimulate the incorporation of [35S]GTP‐γ‐S into DA D2Long receptors. The present study was done to examine whether such glutamatergic drugs had similar… Expand
Glutamate agonist LY404,039 for treating schizophrenia has affinity for the dopamine D2High receptor
TLDR
A possible clinical antipsychotic action of LY404,039 may depend on the combined stimulation of glutamate receptors and a partial dopamine agonist action that would interfere with neurotransmission at D2High receptors. Expand
Dopamine D2High receptors stimulated by phencyclidines, lysergic acid diethylamide, salvinorin A, and modafinil
TLDR
It is concluded that phencyclidine and other psychostimulants and hallucinogens can stimulate dopamine D2 receptors at concentrations related to their behavioral actions. Expand
Glutamate agonists for treating schizophrenia have affinity for dopamine D2High and D3 receptors
TLDR
The findings indicate that this type of glutamate agonist, LY 379,268, has a significant affinity for D2High and D3 receptors. Expand
The dopaminergic stabilizer ASP2314/ACR16 selectively interacts with D2High receptors
TLDR
With similar concentrations of ASP2314 inhibiting the binding of ligands at D2High and stimulating [35S]GTP‐γ‐S incorporation, the data indicate that the dopaminergic stabilizing action of AS2314 may be related to the selectivity for the D2high state of the D1 receptor. Expand
Glutamate receptor mGlu2 and mGlu3 knockout striata are dopamine supersensitive, with elevated D2High receptors and marked supersensitivity to the dopamine agonist (+)PHNO
TLDR
The data suggest that group II mGlu receptors—mGlu2 receptors in particular—may normally regulate D2 receptors by reducing the proportion of high‐affinity D2 receptor in membranes, which may contribute to the antipsychotic action of mGLU2/3 receptor agonists. Expand
Short Communication Glutamate Receptor mGlu2 and mGlu3 Knockout Striata are Dopamine Supersensitive, With Elevated D2 High Receptors and Marked Supersensitivity to the Dopamine Agonist (1)PHNO
TLDR
Data suggest that group II mGlu receptors—mGlu2 receptors in particular—may normally regulate D2 receptors by reducing the proportion of high-affinity D2 receptor in membranes in membranes, which may contribute to the antipsychotic action of mGLU2/3 receptor agonists. Expand
The Dopamine D1-D2 Receptor Heteromer Localizes in Dynorphin/Enkephalin Neurons
The distribution and function of neurons coexpressing the dopamine D1 and D2 receptors in the basal ganglia and mesolimbic system are unknown. We found a subset of medium spiny neurons coexpressingExpand
Glutamate and dopamine components in schizophrenia.
  • P. Seeman
  • Psychology, Medicine
  • Journal of psychiatry & neuroscience : JPN
  • 2009
TLDR
Assessing the basic and clinical findings shows that phencyclidine has DA D(2) agonist actions as well, and the clinical antipsychotic action of a glutamate agonist may depend on its ability to interfere with DA neurotransmission by its DA partial agonism. Expand
Dopamine D2 receptors as treatment targets in schizophrenia.
  • P. Seeman
  • Medicine
  • Clinical schizophrenia & related psychoses
  • 2010
TLDR
Animal models of psychosis show that a variety of risk factors, genetic and nongenetic, are associated with behavioral supersensitivity to dopamine, reflected in elevated levels of dopamine D2High receptors, and long-term use of traditional antipsychotics can further enhance dopamine supersensitivity in patients. Expand
Acute and subchronic PCP attenuate D2 autoreceptor signaling in substantia nigra dopamine neurons
TLDR
The effects of PCP on dopaminergic signaling in the midbrain could enhance burst firing and contribute to the development of schizophreniform behavior. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 76 REFERENCES
Dopamine partial agonist actions of the glutamate receptor agonists LY 354,740 and LY 379,268
TLDR
The dopamine agonist and antagonist actions of these compounds indicate that these drugs have properties of a dopamine partial agonist, and may, therefore, have antipsychotic action. Expand
Modulation of stress-induced and stimulated hyperprolactinemia with the group II metabotropic glutamate receptor selective agonist, LY379268
TLDR
Results indicate that stimulation of mGlu2/3 has an indirect inhibitory action on pituitary prolactin release, and it is speculated that disinhibition of tubero-infundibular DA release by presynaptic Group II mGLU receptors located on inhibitory inputs to the arcuate hypothalamic nucleus is a possible explanation for the findings. Expand
Targeting the dopamine D2 receptor in schizophrenia
  • P. Seeman
  • Medicine
  • Expert opinion on therapeutic targets
  • 2006
TLDR
The antipsychotic receptor was a dopamine receptor, now named the dopamine D2 receptor, a major targeting site in schizophrenia, and the antipsychotics are thought to specifically target these D2High states in psychosis in general and schizophrenia in particular. Expand
Dopamine receptor contribution to the action of PCP, LSD and ketamine psychotomimetics
TLDR
To determine the affinities of phencyclidine, ketamine, dizocilpine and LSD for the functional high-affinity state of the dopamine D2 receptor, D2High, their dissociation constants (Ki) were obtained on [3H]domperidone binding to human cloned dopamine D 2 receptors. Expand
Increased dopamine D2High receptors in amphetamine‐sensitized rats, measured by the agonist [3H](+)PHNO
Repeated injections of amphetamine causes animals to become sensitized and supersensitive to DA. Previous work showed that the striata from such sensitized rats revealed a 3.5‐fold increase in theExpand
In vitro biochemical evidence that the psychotomimetics phencyclidine, ketamine and dizocilpine (MK-801) are inactive at cloned human and rat dopamine D2 receptors.
TLDR
Phencyclidine, ketamine and dizocilpine lacked dopamine D2 receptor full agonist, partial agonist and antagonist activity in these assays, suggesting their psychotomimetic effects, and activity in rodent models of schizophrenia, are associated with N-methyl-d-aspartate receptor blockade rather than a direct interaction with dopamine D 2 receptors. Expand
Phencyclidine and Dizocilpine Induced Behaviors Reduced by N-acetylaspartylglutamate Peptidase Inhibition via Metabotropic Glutamate Receptors
TLDR
These data support the proposal that NAAG peptidase inhibition and elevation of synaptic N AAG levels represent a new therapeutic approach to treating the positive and negative symptoms of schizophrenia that are modeled by open channel NMDA receptor antagonists. Expand
The metabotropic glutamate 2/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus d-amphetamine motor behaviors in rats.
TLDR
The marked mGlu2/3 receptor-mediated inhibitions of PCP-evoked behaviors by LY354740 and LY379268, with minimal effects on AMP, may indicate potential antipsychotic effects in humans in the absence of dopamine mediated extrapyramidal side effects. Expand
Antiparkinson therapeutic potencies correlate with their affinities at dopamine D2High receptors
TLDR
D2High is the primary and common target for the antiparkinson action of dopamine agonists, and there was a clear correlation between the Ki values at D2High and their therapeutic concentrations in the plasma water, as derived from the known concentrations after correction for the fraction bound to the human plasma proteins. Expand
NAAG peptidase inhibition reduces locomotor activity and some stereotypes in the PCP model of schizophrenia via group II mGluR
TLDR
The view that NAAG peptidase inhibitors may represent a new therapeutic approach to some of the components of schizophrenia that are modeled by PCP is supported. Expand
...
1
2
3
4
5
...